The Management Board of Genomtec S.A. has passed a resolution to determine how to distribute funds from a potential technology sale. The Company’s intention is for shareholders to benefit from a potential M&A transaction to the fullest extent possible. As part of its ongoing review of strategic options, Genomtec is working with a transaction advisor, Clairfield Partners LLC, based in New York.